Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Validating Consensus on Post TAVR Conduction Disturbances in the Clinical Practice

Little over a year ago, JACC published the expert consensus on the management of post transcatheter aortic valve replacement (TAVR) conduction disturbances. This publication homogenized criteria and was welcomed by operators who, when in doubt, tended to prematurely indicate definite pacemaker implantation or delayed discharge in order to monitor patients. 

El consenso sobre trastornos de conducción post TAVI a prueba en la práctica clínica

These criteria, however, was nothing but expert consensus to be validated over time, especially in the daily clinical practice

This analysis was based on a registry that classified patients using the consensus algorithm: patients eligible for early discharge (1 or 2 days after TAVR); patients at high risk of high degree atrioventricular block who require additional monitoring; and patients with pacemaker indication. 

Primary end point was pacemaker implantation rate for high degree or complete block at 30 days. All patients with prior pacemaker, valve in valve or electrocardiogram were excluded. 

Of 1439 patients undergoing TAVR between 2014 and 2019, 73% were eligible for early discharge, 21% were at high risk of complete block and the remaining 6% required pacemaker implantation. 


Read also: Experts Reach Consensus on Post TAVR Pacemaker Indication.


Pacemaker implantation rate 30 days after TAVR was 16% (234 patients). 2.7% of the group eligible for early discharge finally required a pacemaker within 30 days after TAVR, and so did 41% of the high-risk group and 100% of those with pacemaker indication. 

Conclusion

The expert consensus on post TAVR conduction disturbances was able to safely identify patients needing a pacemaker. This strategy allows a more uniform management, facilitates early discharge of low-risk patients, and prevents prolonging unnecessary monitoring 3 out of 4 patients

Original Title: Validation of the 2019 Expert Consensus Algorithm for the Management of Conduction Disturbances After TAVR.

Reference: Daniel Malebranche et al. J Am Coll Cardiol Intv. 2021 May, 14 (9) 981–991.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...